|
Post by mnkdfann on Dec 14, 2018 8:34:42 GMT -5
|
|
|
Post by mnkdfann on Dec 13, 2018 23:35:31 GMT -5
I was nosing about on the ANVISA website tonight. They are a busy group (e.g. simplified registration of 43,680 new cosmetics in 2017). Here are some stats from their annual report for 2017. They seem to be working on reducing wait times for approval of new drugs... See also: mnkd.proboards.com/thread/10573/brazils-anvisa-eliminate-backlog-2019
|
|
|
Post by mnkdfann on Dec 13, 2018 20:39:42 GMT -5
Looks like BIOM3 has been Up ever since the BIOM3 & MNKD Afrezza Distribution Announcement Back on May 31st. Brazil, May 31, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) and BIOMM SA (BVMF:BIOM3) today announced that they have entered into a supply and distribution agreement for the commercialization of Afrezza® (insulin human) Inhalation Powder in Brazil.More likely that jump was in response to their successful completion of the rights offering to complete the work on their insulin manufacturing plant. Up until that point it wasn't clear they could complete the factory hence the jump when they got the money. Whatever the reason was, that pop did not last and Biomm's share price is down to 8 (BRL) and change today. It will be interesting to see if approval squeaks in before the end of 2018 to meet the expectation set over a year ago.
|
|
|
Post by mnkdfann on Dec 13, 2018 20:18:05 GMT -5
I'll predict 640 and 910K for tomorrow.
|
|
|
Post by mnkdfann on Dec 13, 2018 20:06:13 GMT -5
The report is NOT fake news, but according to the disclosures it WAS paid for my Mannkind or its agent: "Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request." While some might view that as discouraging, the optimist may take it as encouraging in the sense this may indicate that Mannkind is very interested in actively protecting its pumping share price, and may use other promotional tools of the trade to get the share price high enough and soon enough for the outstanding warrants to be exercised or prepare for a pipe funding. If someone is going to change someone else's words, I wish they would do it outside of the quote level. I know you mean no harm, but there are people on this board who are now going to think I said those things you highlighted.
|
|
|
Post by mnkdfann on Dec 13, 2018 13:37:17 GMT -5
from the earnings call: "David has done a tremendous amount of work not only on the thought leaders, but the scientific publications, which -- one of the problems that we see is when you go to talk about guidelines and changing guidelines, when you don't have any data published, we're sitting on 65 trials and thousands of patients, they need that data published in order to look at adjusting guidelines or highlighting unique aspects of our product, and so that's a major effort of ours. And you've seen probably this year 10 -- you'll see 10 new publications by the end of the year or early next year come out."On its website, Mannkind includes various poster presentations as publications. So it may be that he was including presentations in his 10 count? Either way, more pubs should be expected soon. www.mannkindcorp.com/research-development/publications/
|
|
|
Post by mnkdfann on Dec 13, 2018 13:08:44 GMT -5
from the earnings call: "David has done a tremendous amount of work not only on the thought leaders, but the scientific publications, which -- one of the problems that we see is when you go to talk about guidelines and changing guidelines, when you don't have any data published, we're sitting on 65 trials and thousands of patients, they need that data published in order to look at adjusting guidelines or highlighting unique aspects of our product, and so that's a major effort of ours. And you've seen probably this year 10 -- you'll see 10 new publications by the end of the year or early next year come out."AFAIK, no one else has previously remarked upon this but coincidentally Mannkind's booth at the ADA is right by that of Mary Ann Liebert, Inc. Publishers. Mannkind published (at least one) of its papers in one of Mary Ann's journals earlier this year. Unfortunately it is not the most prestigious of publishing houses (I mean its journals are not on the level of the Lancet or JAMA etc.), but I guess it is a perfectly okay middle of the road publisher, and anything helps. I doubt the above is anything more than coincidence. But it is what it is. Maybe Mary Ann's booth will have copies of that Mannkind paper I mentioned to hand out. Or Mannkind's booth highlights its paper in ML's journal at its own booth, and earns good karma from ML towards its future submissions. Feel the synergies!
|
|
|
Zacks
Dec 13, 2018 12:05:23 GMT -5
Post by mnkdfann on Dec 13, 2018 12:05:23 GMT -5
Zacks SCR "initiated" coverage (which I guess just means publishing the article in this case). It didn't upgrade an existing price target. I'm guessing that MNKD did not instruct Zacks SCR how to write the report and how to come up with a value. Zacks SCR is, after all, putting the article out there with their name on it and whatever reputation they have on the line... I don't disagree, and FWIW I never claimed MNKD told Zacks SCR what to write, or that they did not stand behind their price target.
|
|
|
Post by mnkdfann on Dec 13, 2018 0:50:08 GMT -5
100% Hemp from Tegridy Farms.
|
|
|
Post by mnkdfann on Dec 12, 2018 19:58:03 GMT -5
|
|
|
Zacks
Dec 12, 2018 17:38:30 GMT -5
Post by mnkdfann on Dec 12, 2018 17:38:30 GMT -5
How, exactly, does one upgrade when one initiates coverage? LOL Of course they couldn't, that was my point (and was in response to someone who described it as an upgrade). It was an initiation of coverage, not an upgrade.
|
|
|
Zacks
Dec 12, 2018 16:29:07 GMT -5
Post by mnkdfann on Dec 12, 2018 16:29:07 GMT -5
While mnkd May have sponsored the article (it was articulate and flowed very logically) they don’t pay for upgrades as far as I know. So zacks upgrades and supports with a very well reasoned article published by mnkd. Good by me! Zacks SCR "initiated" coverage (which I guess just means publishing the article in this case). It didn't upgrade an existing price target.
|
|
|
Zacks
Dec 12, 2018 16:00:34 GMT -5
Post by mnkdfann on Dec 12, 2018 16:00:34 GMT -5
I saw the article pop up on my main page Yahoo feed, but that's mostly just because of how well Yahoo/Google knows me. Of course I stupidly checked the comments section and saw the usual mess of "OMG PAID REPORT, FAKE NEWS!!!!", "MNKD SUCKZZZ, GOING BANKRUPT!!!" The report is NOT fake news, but according to the disclosures it WAS paid for my Mannkind or its agent: "Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request." While some might view that as discouraging, the optimist may take it as encouraging in the sense this may indicate that Mannkind is very interested in actively protecting its share price, and may use other promotional tools of the trade to get the share price high enough and soon enough for the outstanding warrants to be exercised.
|
|
|
Post by mnkdfann on Dec 12, 2018 10:25:41 GMT -5
|
|
|
Post by mnkdfann on Dec 10, 2018 22:00:37 GMT -5
I've said it before and I'll say it again ads are the key to selling afrezza. Mike needs to remember we are not a major pharma and can't do business like they do. The boring ass commercials all drug companies make stink I mean really stink. So we are in a position to do something different, better something never done. Make a hard hitting funny commercial that people will watch and take notice of. People will talk about about it hey did you see that commercial with the... What we are doing is not working Mnkd needs to dare to be different our survival depends on it. An idea for the comercial could be like this: Which would you rather (You have to picture it) 1.A woman kicking a man in the nuts or The woman kissing the man. 2.A man shoveling snow by hand with a small shovel or a man using a brand new snow blower. 3.A man violently jabbing himself with a needle or a man smiling after inhaling Afrezza. I'm not a comedian but you see where I'm going anything would be better than what we have now. A small start up ad agency looking to make a name could really run with making a funny commercial. Mannkind's last ad was Golden: investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-inhaled-insulin-television-advertising-campaign-wins"Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity"
|
|